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Abstract
Particulate air pollution (PM) exposure has been associated with cancer incidence and mortality 
especially with lung cancer. The liver is another organ possibly affected by PM due to its role in 
detoxifying xenobiotics absorbed from PM. Various studies have investigated the mechanistic 
pathways between inhaled pollutants and liver damage, cancer incidence, and tumor progression. 
However, little is known about the effects of PM on liver cancer survival.
20,221 California Cancer Registry patients with hepatocellular carcinoma (HCC) diagnosed 
between 2000–2009 were used to examine the effect of exposure to ambient PM with diameter 
less than 2.5µm (PM2.5) on HCC survival. Cox proportional hazards models were used to estimate 
hazard ratios (HRs) relating PM2.5 to all-cause and liver cancer-specific mortality linearly and 
non-linearly— overall and stratified by stage at diagnosis (local, regional, and distant)—adjusting 
for potential individual and geospatial confounders.
PM2.5 exposure after diagnosis was statistically significantly associated with HCC survival. After 
adjustment for potential confounders, the all-cause mortality HR associated with a 1 standard 
deviation (5.0 µg/m3) increase in PM2.5 was 1.18 (95% CI: 1.16 – 1.20); 1.31 (95% CI:1.26 – 
1.35) for local stage, 1.19 (95% CI:1.14 – 1.23) for regional stage, and 1.05 (95% CI:1.01 – 1.10) 
for distant stage. These associations were nonlinear, with substantially larger HRs at higher 
exposures. The associations between liver cancer-specific mortality and PM2.5 were slightly 
attenuated compared to all-cause mortality, but with the same patterns.
Exposure to elevated PM2.5 after the diagnosis of HCC may shorten survival, with larger effects at 
higher concentrations.
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Introduction
Air pollution is classified as a carcinogen by the International Agency for Research on 
Cancer (IARC).1 While associations between ambient particulate matter with diameter less 
than 2.5µm (PM2.5) and lung cancer have been well documented, associations with cancers 
at other sites have received less attention.2 The liver may be a target as PM2.5 can induce 
oxidative stress, inflammation, genotoxicity, and accelerate liver inflammation and steatosis, 
driving the development and progression of liver cancer.3 For example, PM2.5 exposure has 
been linked to increased serum levels of hepatic enzymes such as alanine aminotransferase 
(ALT), which is a marker of liver damage and a predictor of hepatocellular carcinoma 
(HCC), the most common liver cancer.4 Long-term PM2.5 exposures have recently been 
linked to an increased incidence of HCC,4 but the effects of PM2.5 exposure on survival of 
HCC have not been investigated. We hypothesized that PM2.5 exposure accelerates the 
progression of HCC and decreases survival after the diagnosis of liver cancer.
Materials and Methods
To determine whether PM2.5 exposure is associated with survival in liver cancer patients, we 
combined data on patients newly diagnosed with primary HCC (ICD-O-3 site code of C22.0 
and morphology codes of 8170–81765) between 2000–2009 from the California Cancer 
Registry (CCR) (http://www.ccrcal.org) and PM2.5 air pollution data collected by the U.S. 
Environmental Protection Agency’s (EPA) Air Quality System (AQS) database6 for the 
same time period, using the same methods as described in detail in a previous study.7 
Briefly, the CCR data contain information on patient demographics, routine follow-up on 
vital status, tumor characteristics (including stage of diagnosis), and first course of treatment 
within 6 months of diagnosis for all HCC patients diagnosed in California. Cancer records 
were geocoded by longitude and latitude based on residential address at diagnosis, and then 
assigned into census tracts and block groups for assignment of area-based estimates of rural-
urban commuting area (RUCA) codes and socioeconomic status (SES). Specifically, RUCA 
codes are census tract-level designations from 1 (metropolitan) to 10 (rural) based on the 
size and direction of primary commuting flows, using measures of population density, 
urbanization, and daily commuting (www.ers.usda.gov/data-products/rural-urban-
commuting-area-codes.aspx).8 Socioeconomic status was calculated at the census block 
group level using validated area-level measures based on census 2000 data and American 
Community Survey 2007–2011 5-year estimates (online supplement).9–11 Routine CCR 
follow-up of cancer patients monitored patient vital status through information sharing with 
reporting hospitals and linkage with a variety of administrative records.12 There were 20,221 
eligible HCC cases with PM2.5 exposures included in the analysis. We censored the date of 
last follow-up to December 31, 2011.
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Using hourly measurements of ambient PM2.5 (in µg/m3) in the AQS database, monthly 
average PM2.5 concentrations were calculated from hourly and daily measurements6, and 
spatially interpolated to residence locations from up to four closest air quality monitoring 
stations using inverse distance-squared weighting.7,13 PM2.5 exposures were not assigned to 
patient residences with unmatched geocodes or with the nearest monitor located > 25km 
away. Survival-period exposure summaries were calculated as the average ambient 
residential monthly PM2.5 from date of diagnosis to date of death or loss to follow-up or the 
end of study.
Kaplan-Meier curves were used to calculate median survival stratified by stage at diagnosis 
and categorized PM2.5 exposure. Cox proportional hazards models were used to estimate the 
PM2.5 exposure (<10 µg/m3, 10–25 µg/m3, >25 µg/m3) and survival association. We 
considered both all-cause and liver cancer specific mortality, where liver cancer was the 
underlying cause of death on the death certificate (ICD-10 code C22.0-C22.9).14 Patient 
survival was censored due to loss to follow-up or study end (or, for liver cancer specific 
mortality, censored due to death by another cause). Hazard ratios (HRs)—scaled to a 
standard deviation (SD) increase in PM2.5—were obtained from Cox models that adjusted 
for predetermined potential confounders: age, sex, race/ethnicity (non-Hispanic white, 
Hispanic, non-Hispanic black, Asian/Pacific islanders, other/unknown), marital status 
(single, married, formerly married, unknown), year of diagnosis, month of diagnosis, and 
initial treatment (surgery, radiation, and/or chemotherapy versus none), SES, dichotomized 
RUCA (metropolitan core, non-metropolitan core), categorized distance to primary interstate 
highways and primary US and State Highways (<300m, 300–1500m, >1500m). Adjusted 
Cox models were stratified by tumor stage at diagnosis (local, regional, distant). Sensitivity 
analyses were performed by further stratifying the stage-specific Cox models by distance to 
monitor, geocoding accuracy (street-level matching vs. city-level matching), regions (Los 
Angeles county, San Francisco Bay Area, San Diego county, and other regions in 
California), and socioeconomic status. Nonlinear associations with PM2.5 were examined 
using a natural cubic spline with 2 degrees of freedom2 and Cox models with categorized 
PM2.5.
Analyses were conducted using SAS version 9.4 (SAS Institute Inc.) and R version 3.3.1 
(http://www.R-project.org). Hypothesis tests were 2-sided with a 0.05 significance level.
Results
Overall, median survival was 0.64 years and only 324 patients were lost to follow-up (i.e., 
not known to be dead and with a last follow-up date 15 months or longer before the study 
end). HCC patients were on average 63.7 years old at diagnosis, racially diverse (38.9% non-
Hispanic white, 25.9% Hispanic white, 26.1% Asian/Pacific islander) and predominantly 
male (75.0%), and living in metropolitan core areas (90.6%) (Table 1). The most common 
stage at diagnosis was local (44.8%) followed by: regional (27.5%), distant (17.6%), and 
unknown (10.0%). The number of patients diagnosed at local stage increased from 533 
(5.9%) in 2000 to 1347 (14.9%) in 2009 while the number decreased from 548 (15.4%) to 
395 (11.1%) in distant stage (data not shown). The most common initial treatments were 
chemotherapy (32.4%) and surgery (21.9%). In general, patients who lived in areas with 
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high PM2.5 tended to have lower socio-economic status and were more likely to be 
diagnosed with advanced stage disease (eTable1).
Median all-cause mortality times were higher in low PM2.5 areas for patients diagnosed at 
either local or regional stage (Table 2). For example, median survival times for patients 
diagnosed at local stage living in lowest and highest PM2.5 exposure areas were 2.16 and 
0.07 years, respectively. After adjusting for potential confounders, PM2.5 level was inversely 
associated with all-cause mortality with statistical significance. Allowing for nonlinear 
associations using splines or categorized exposure, the adjusted PM2.5 HR for all-cause 
mortality were significantly higher in high exposure areas in both overall and in stage-
specific models (Figure 1, Table 2). In stage-specific models using a linear term for 
continuous PM2.5 exposure, the HRs associated with a 1 SD increase in PM2.5 were 1.31 
(95% CI: 1.26 – 1.35) for local stage, 1.19 (95% CI: 1.14 – 1.23) for regional stage, and 1.05 
(95% CI: 1.01 – 1.10) for distant stage. This indicates the damaging effect of PM2.5 is most 
substantial for patients with local disease and diminishes with worsened stage, which likely 
reflects the shortened survival/exposure time for patients with late stage disease. The 
associations between liver cancer specific survival and exposure to PM2.5 were slightly 
attenuated, but the pattern that adjusted PM2.5 HR was larger for patients diagnosed at early 
stage remained (eTable 2). Sensitivity analyses show that stage-stratified HRs were robust to 
stratification by distance to monitor, geocoding accuracy, and socioeconomic status (eTable 
3). Stratification by various metropolitan areas (LA county, San Diego county, San Francisco 
Bay Area) showed a consistent pattern of larger PM2.5 HR for patients with local stage at 
diagnosis as compared to patients with more advanced stage at diagnosis.
Discussion
Our study provides the first evidence that exposure after HCC diagnosis to a major ambient 
air pollutant, PM2.5, is associated with shortened survival. These associations were strongest 
for patients diagnosed at local stage and showed larger adverse effects at higher PM2.5 
levels. To our knowledge, no study has related PM2.5 to liver cancer survival, but several 
have examined other PM2.5-liver cancer associations.2,4 For instance, in a large cohort study 
(n=66,820) Wong et al found that PM2.5 was associated with mortality from accessory organ 
cancers (liver, gall bladder, and pancreas) (overall: 1.35 (95% CI: 1.06–1.71), in males: 1.28 
(95% CI: 0.83–1.96), in females: 1.37 (95% CI: 1.05–1.80), and in female never smokers: 
1.36 (95% CI: 1.01–1.84)).2 A key difference between our study and the Wong et al study is 
that we calculated the average PM2.5 exposure after diagnosis, addressing the hypothesis that 
PM2.5 exposure after diagnosis adversely affects survival. Wong et al assigned exposures 
based on the subjects' recruitment year average (between 1998 and 2001). Our study 
specifically targeted HCC and conducted stage-specific analysis, which limits carry-over 
effects at diagnosis.
Our population-based study design—consisting of all Californian HCC cases between 2000–
2009—minimizes selection and survivorship bias. California also has one of the largest and 
longest running air pollution monitoring networks and a wide range of PM2.5 exposures 
allowing large valid scale exposure assessment using standard methods. Residential 
addresses were available only at the date of diagnosis, so there could be exposure 
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misclassification due to patients relocating. However, patients with HCC were less likely to 
relocate after diagnosis as the survival times were very short. An important limitation of our 
registry-based design is that personal-level data (e.g., alcohol consumption, Hepatitis A/B 
status, weight, and residential histories after diagnosis) were not available in the CCR. We 
did control for area-level SES and rural/urban factors, major confounders to the PM2.5-HCC 
survival associations, and believe that factors other than SES and residential location were 
unlikely to be associated with the spatio-temporal distribution of ambient air pollution 
exposures. Thus, the associations could not have spuriously induced with the adjustment of 
these omitted factors. Nevertheless, future studies should consider additional personal-level 
factors.
Previous studies have suggested exposure-response relationships for PM2.5 that were linear 
for lung cancer mortality or steeply increasing at low exposure levels and flattening out at 
higher exposures for cardiovascular mortality.15–16 On the one hand, our finding of 
nonlinear (concave upward, quadratic curved) PM2.5-HCC survival associations has 
significant public health implications, providing evidence that relatively small reductions in 
high pollution levels could have substantial health impacts. On the other hand, the 
magnitude of the hazard ratios at the high pollution levels were large. While these findings 
were plausible and consistent with the results from the analysis on the linear association, we 
recognize there might be unmeasured risk factors such as those personal-level confounders 
that are not available in our data. Future research is needed to confirm this finding.
In summary, we found adverse effects of PM2.5 exposure after diagnosis on liver cancer 
survival. Not only were such effects more profoundly for those diagnosed with early stage, 
but they also increased strongly with concentration, suggesting that reductions in high PM2.5 
exposure could increase survival for a non-respiratory system cancer.
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Novelty & Impact Statements
This is the first registry-based study to link individual-level estimates of air pollution 
exposures after liver cancer diagnosis to survival on a population-based sample of 20,221 
patients with newly diagnosed liver cancer during 2000–2009 in California. We found 
adverse effects of PM2.5 exposure after diagnosis on liver cancer survival increased 
strongly with concentration, suggesting that reductions in high PM2.5 exposure could 
increase survival for a non-respiratory system cancer.
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Nonlinear patterns of adjusteda associations between PM2.5 exposure and all-cause mortality 
(solid line) and 95% confidence interval (dashed line) estimated using a natural cubic spline 
with 2 degrees of freedom. Points with confidence intervals are hazard ratios and 95% 
confidence intervals for all-cause mortality from pooled and stage-specific Cox proportional 
hazard models with categorized PM2.5 exposure.b The distribution of PM2.5 exposures are 
demarcated using ticks above the x-axis.c
a Adjusted for age, sex, race/ethnicity, marital status, socioeconomic status, rural–urban 
commuting area, distance to primary interstate highway, distance to primary US and state 
highways, month of diagnosis, year of diagnosis and initial treatments.
b The categories of PM2.5 exposure were 0–10, 10–15, 15–20, 20–25, 30+ µg/m3. The 
hazard ratios for all-cause mortality from pooled and stage-specific Cox proportional hazard 
models with categorized PM2.5 exposure are presented in Table 2 and plotted at 5, 12.5, 
17.5, 22.5, and 35 µg/m3 in the Figure 1.
c Three patients with PM2.5 exposure > 50 µg/m3 were excluded from the plot (but not the 
model).
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